Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

695P - Second-line envafolimab and beyond in locally advanced or metastatic non-small cell lung cancer

Date

07 Dec 2024

Session

Poster Display session

Presenters

Maojing Guan

Citation

Annals of Oncology (2024) 35 (suppl_4): S1632-S1678. 10.1016/annonc/annonc1698

Authors

M. Guan, Q. Shi

Author affiliations

  • Internal Oncology Department, AnHui Chest Hospital, 230022 - Hefei/CN

Resources

This content is available to ESMO members and event participants.

Abstract 695P

Background

Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors have become an important treatment in both monotherapy and combination therapy for advanced non-small cell lung cancer (NSCLC). Envafolimab, a humanized subcutaneous PD-L1 monoclonal antibody, has been approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors. We conducted an open-label, non-randomised, phase II study to evaluate the efficacy and safety of envafolimab in patients with previously treated, locally advanced or metastatic NSCLC (ClinicalTrials.gov: NCT 05529355).

Methods

Patients received subcutaneous envafolimab 150mg every week, combined with chemotherapy or anti-vascular endothelial growth factor receptor treatment. The primary end point was objective response rate (ORR), and the second end points included disease control rate (DCR), progression-free survival (PFS), and safety.

Results

Of the 20 patients enrolled in this study, a 15% ORR and 70% DCR were observed. Median PFS was five months (95% CI 3.643-6.357). Median OS was 38 months (95% CI 26.936–49.064). In the multivariate Cox regression model, the presence of actionable genomic alterations were significant risk factors for poor PFS (P=0.037, HR=5.702). The most common adverse event was immune-related endocrinopathies (35%, 7/20). Of 18 patients received programmed death-1 (PD-1) inhibitors on first-line treatment, 1/3 (n=6) patients switched to envafolimab for adverse events of first-line immune therapy and no new safety signals were observed. No grade 4 adverse events or treatment-related death occurred.

Conclusions

Envafolimab is efficient, safe and convenient as second-line treatment for locally advanced or metastatic NSCLC, especially for those with unbearable PD-1 related toxicity.

Clinical trial identification

NCT 05529355.

Editorial acknowledgement

Legal entity responsible for the study

China International Medical Foundation.

Funding

China International Medical Foundation [No. Z2014-06-2201].

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.